In this article, we will discuss: 12 Best Genomics Stocks to Invest In.
Companies that study DNA to improve people’s lives are known as genomics stocks. These businesses often fit into one of three groups: genetic editing, genetic testing and diagnosis, or genetic sequencing and analysis.
Bloomberg reported on October 31, 2025, that the U.S. Food and Drug Administration announced a new regulatory route to expedite approvals for tailored gene-editing therapies. Vinay Prasad, the FDA’s director of gene therapies, stated that the agency is now allowing combination clinical trials involving individuals with associated genetic conditions, a departure from the previously required separate research for each disease.
According to Prasad, this approach takes advantage of CRISPR technology advancements and enables regulators to act more rapidly and readily, especially for extremely rare disorders that affect small patient populations. He stated that the policy aims to promote development and investment in areas that were previously thought to be commercially unsustainable.
Recently, in a report published in the American Journal of Human Genetics, researchers from the Children’s Hospital of Philadelphia and the University of Pennsylvania detailed how the FDA has permitted platform studies in which only the guide RNA is edited for certain mutations. As per the researchers, the approach might lower development costs and increase access to disorders, including phenylketonuria and urea cycle conditions.
With that said, here are the 12 Best Genomics Stocks to Invest In.
Photo by National Cancer Institute on Unsplash
Methodology:
We sifted through the online rankings to form an initial list of the 20 Best Genomics Stocks to Invest In. From the resultant dataset, we chose the 12 Best Genomics Stocks with the highest number of hedge fund holders for each stock using Insider Monkey’s database of hedge funds as of Q3 2025. We also considered analysts’ upside potential of over 15%, as of December 24. Finally, we ranked these stocks in ascending order based on hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
12. Personalis, Inc. (NASDAQ:PSNL)
Number of Hedge Fund Holders: 7
Analysts’ Upside Potential as of December 24: 26.15%
Personalis, Inc. (NASDAQ:PSNL) is among the Best Genomics Stocks.
The Fly reported on December 2, 2025, that Morgan Stanley analyst Kallum Titchmarsh took over coverage of Personalis, Inc. (NASDAQ:PSNL) with an Equal Weight rating and a price objective of $11, up from $9. The firm identified several upcoming catalysts within its coverage universe starting in 2026 and outlined growing bright spots across life science instruments and diagnostics end markets. Morgan Stanley claimed that a valuation surge in the second half of the year left industry multiples at fair levels despite favorable sector dynamics, prompting the bank to start coverage with an In-Line industry stance.
In addition, Personalis, Inc. (NASDAQ:PSNL) lowered its full-year 2025 sales forecast from $70 million to $80 million to a range of $68 million to $73 million. The projected income from pharmaceutical testing, services, and other clients has been reduced from $52 million to $58 million to $50 million to $54 million.
In contrast to previous projections of $15 million to $16 million, revenue from population sequencing and enterprise clients was raised to $16.5 million to $17 million. Clinical test reimbursed revenue has dropped from $3 million to $6 million to $1.5 million to $2 million. Gross margin estimate of 22% to 24%, net loss of about $85 million, and cash consumption of about $75 million were all reiterated by the business.
Personalis, Inc. (NASDAQ:PSNL) offers genomic sequencing and analytics technologies to help develop tailored cancer vaccines and other next-generation cancer immunotherapies.
11. Absci Corporation (NASDAQ:ABSI)
Number of Hedge Fund Holders: 18
Analysts’ Upside Potential as of December 24: 131.61%
Absci Corporation (NASDAQ:ABSI) is among the Best Genomics Stocks.
Absci Corporation (NASDAQ:ABSI) announced on December 4, 2025, that the first healthy volunteers had been dosed in the Phase 1/2a HEADLINE clinical trial investigating ABS-201, an experimental anti-prolactin receptor antibody built on its generative AI system. The Phase 1/2a trial is intended to evaluate effectiveness, pharmacokinetics, pharmacodynamics, immunogenicity, safety, and tolerability. The trial’s interim results are anticipated in the latter part of 2026. As per the company, ABS-201, which addresses indications in women’s health and dermatology, is a progression of its strategy to take internally produced assets into clinical development. According to founder and CEO Sean McClain, the achievement underlines the use of the AI-driven platform for clinical development and improves the delivery of unique assets.
Following an investor event centered on ABS-201 and its androgenetic alopecia program, the Fly reported on December 17, 2025, that H.C. Wainwright increased its price objective on Absci Corporation (NASDAQ:ABSI) to $8 from $7 and retained a Buy rating. The firm included ABS-201 in its financial model and noted how it might raise the percentage of hair follicles in the growth phase as opposed to the resting period, which is when hair loss takes place. The analyst stated that the strength of the preclinical evidence given throughout the event lends credibility to the ABS-201 program.
Absci Corporation (NASDAQ:ABSI) is an artificial intelligence-powered synthetic biology firm that is unlocking proteins’ potential as the next generation of drugs.
